REXO-C/ANP/siRNA targeting SNCA can act as a nanoscavenger, which could promote clearance of α-synuclein aggregates and improve motor symptoms in a PD mouse model (Liu et al., 2020a). Here, SNCA is linked to Parkinson disease.